Ozempic and Mounjaro, originally diabetes medications, have exploded in popularity as powerful weight-loss injectables.

Eli Lilly and Company ( NYSE: LLY) BofA Securities 2025 Health Care Conference Call May 15, 2025 11:40 AM ET Lucas Montarce - CFO Mike Czapar - SVP, IR ...

Eli Lilly and Company (NYSE:LLY) is a leading medicine company which discovers, develops, manufactures, and markets products ...

While those taking semaglutide (Wegovy) and tirzepatide (Mounjaro) lost double the amount of weight compared with people ...

Less than 3% of all people in the U.S. who are eligible for injectable weight loss drugs get a prescription for it, a new ...

Frier Levitt will host a May 15 webinar on legal risks, compounding regulations and market trends impacting GLP-1 prescribers ...

A new analysis being presented at the European Congress on Obesity (ECO25) in Malaga, Spain (11–14 May), finds that around ...

GLP1 drugs are changing patients eating and grocery shopping habits - 2 News Oklahoma's Cathy Tatom hears how from a patient, ...

Ohio Attorney General Dave Yost sent letters to 14 medical spas warning them to stop making false or misleading claims about ...

If a higher body weight is affecting your ability to get around, or you have joint pain from arthritis, it can impair your ...

In the first head-to-head trial of its kind, people with obesity who took tirzepatide (sold under the brand names Mounjaro ...

For the 2025 outlook, Novo Nordisk now expects 13-21% revenue increase at constant exchange rates (CER). Operating profit is ...